Caricamento...
Identification and targeting of selective vulnerability rendered by tamoxifen resistance
BACKGROUND: The estrogen receptor (ER)-positive breast cancer represents over 80% of all breast cancer cases. Even though adjuvant hormone therapy with tamoxifen (TMX) is saving lives of patients with ER-positive breast cancer, the acquired resistance to TMX anti-estrogen therapy is the main hurdle...
Salvato in:
| Pubblicato in: | Breast Cancer Res |
|---|---|
| Autori principali: | , , , , , , , , , |
| Natura: | Artigo |
| Lingua: | Inglês |
| Pubblicazione: |
BioMed Central
2020
|
| Soggetti: | |
| Accesso online: | https://ncbi.nlm.nih.gov/pmc/articles/PMC7388523/ https://ncbi.nlm.nih.gov/pubmed/32727562 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1186/s13058-020-01315-5 |
| Tags: |
Aggiungi Tag
Nessun Tag, puoi essere il primo ad aggiungerne! !
|